Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-25-20 | Dec-27-19 | Dec-28-18 | Dec-29-17 | Sep-30-16 | Sep-25-15 | Sep-26-14 |
| Revenues | 2,208.8 | 2,213.4 | 3,162.5 | 3,215.6 | 3,221.6 | 3,380.8 | 2,923.1 | 1,650.3 |
| Revenue growth | -0.2% | -30.0% | -1.7% | -0.2% | | 15.7% | 77.1% | -3.6% |
| Cost of goods sold | 1,317.1 | 1,544.0 | 1,741.1 | 1,744.4 | 1,564.1 | 1,523.2 | 1,300.2 | 765.7 |
| Gross profit | 891.7 | 669.4 | 1,421.4 | 1,471.2 | 1,657.5 | 1,857.6 | 1,622.9 | 884.6 |
| Gross margin | 40.4% | 30.2% | 44.9% | 45.8% | 51.4% | 54.9% | 55.5% | 53.6% |
| Selling, general and administrative | 581.8 | 884.1 | 831.0 | 834.1 | 849.7 | 913.7 | 1,023.8 | 611.0 |
| Research and development | 205.2 | 290.8 | 349.4 | 361.1 | 276.9 | 261.2 | 203.3 | 140.5 |
| EBITA | 427.6 | 167.3 | -970.5 | -2,877.7 | 1,282.3 | 1,382.8 | 952.1 | 317.9 |
| EBITA margin | 19.4% | 7.6% | -30.7% | -89.5% | 39.8% | 40.9% | 32.6% | 19.3% |
| Amortization of intangibles | 581.1 | 771.2 | 853.4 | 740.2 | 694.5 | 700.1 | 550.3 | 154.8 |
| EBIT | -153.5 | -603.9 | -1,823.9 | -3,617.9 | 587.8 | 682.7 | 401.8 | 163.1 |
| EBIT margin | -6.9% | -27.3% | -57.7% | -112.5% | 18.2% | 20.2% | 13.7% | 9.9% |
| Pre-tax income | -829.8 | -960.8 | -1,591.5 | -4,052.0 | 61.6 | 233.4 | 107.3 | -34.6 |
| Income taxes | -106.3 | 8.9 | -584.3 | -430.1 | -1,709.6 | -255.6 | -129.3 | -12.6 |
| Tax rate | 12.8% | | 36.7% | 10.6% | | | | 36.4% |
| Earnings from continuing ops | -723.5 | -969.7 | -1,007.2 | -3,621.9 | 1,771.2 | 489.0 | 236.6 | -22.0 |
| Earnings from discontinued ops | | | | | | 0.0 | | |
| Net income | -717.4 | -944.6 | -996.5 | -3,607.0 | 2,134.4 | 643.7 | 324.7 | -319.3 |
| Net margin | -32.5% | -42.7% | -31.5% | -112.2% | 66.3% | 19.0% | 11.1% | -19.3% |
| |
| Diluted EPS | ($8.54) | ($11.48) | ($12.00) | ($43.12) | $18.09 | $4.39 | $2.02 | ($0.34) |
| Shares outstanding (diluted) | 84.7 | 84.5 | 83.9 | 84.0 | 97.9 | 111.5 | 117.2 | 64.9 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|